Xtl Biopharmaceuticals Overview

  • Year Founded
  • 1993

Year Founded

  • Status
  • Public

  • Employees
  • 5

Employees

  • Stock Symbol
  • XTLB

Stock Symbol

  • Investments
  • 7

Xtl Biopharmaceuticals General Information

Description

XTL Biopharmaceuticals Ltd is an intellectual property-based company focused on the development, management, and commercialization of intellectual property. The Company is engaged in biotechnology through its subsidiary Psyga Bio and in the biopharmaceutical industry with hCDR1, a novel compound working via a novel mechanism of action for the treatment of Systemic Lupus Erythematosus (SLE) and a potential treatment for Sjogren's syndrome (SS). It focuses on the acquisition and development of proprietary products and late-stage pharmaceutical product candidates for the treatment of unmet clinical needs.

Contact Information

Website
www.xtlbio.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 5 Badner Street
  • PO Box 8241
  • Ramat Gan 5218102
  • Israel
+972
Primary Industry
Drug Discovery
Stock Exchange
TAE
Corporate Office
  • 5 Badner Street
  • PO Box 8241
  • Ramat Gan 5218102
  • Israel
+972

Xtl Biopharmaceuticals Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Xtl Biopharmaceuticals Stock Performance

As of 19-Nov-2026, Xtl Biopharmaceuticals’s current market cap is $3.9M with 983M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.9M 983M 753K

Xtl Biopharmaceuticals Financials Summary

As of 31-Dec-2025, Xtl Biopharmaceuticals has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 31-Dec-2025 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 6,472 6,472 14,109 3,095
Revenue 0 0 0 0
EBITDA (812) (812) 433 (1,823)
Net Income (6,969) (6,969) (1,027) (1,782)
Total Assets 166 166 8,550 2,426
Total Debt 269 269 138 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Xtl Biopharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Xtl Biopharmaceuticals‘s full profile, request access.

Request a free trial

Xtl Biopharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
XTL Biopharmaceuticals Ltd is an intellectual property-based company focused on the development, management, and commerc
Drug Discovery
Ramat Gan, Israel
5 As of 2026

Yardley, PA
 

Bengaluru, India
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Xtl Biopharmaceuticals Competitors (21)

One of Xtl Biopharmaceuticals’s 21 competitors is Savara, a Formerly VC-backed company based in Yardley, PA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Savara Formerly VC-backed Yardley, PA
Biocon Formerly PE-Backed Bengaluru, India
Novartis Corporation Basel, Switzerland
Vicore Pharma Holding Formerly VC-backed Stockholm, Sweden
Lilly USA Corporation Indianapolis, IN
You’re viewing 5 of 21 competitors. Get the full list »

Xtl Biopharmaceuticals Patents

Xtl Biopharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20180043016-A1 Pharmaceutical compositions comprising 0.25 mg dose of synthetic human peptides for treating systemic lupus erythematosus Inactive 11-Aug-2016
US-20200338195-A1 Pharmaceutical compositions comprising 0.25 mg dose of synthetic human peptides for treating systemic lupus erythematosus Inactive 11-Aug-2016
US-20180043017-A1 Pharmaceutical compositions comprising 0.5 mg dose of synthetic human peptides for treating systemic lupus erythematosus Inactive 11-Aug-2016
US-20090054477-A1 4-thio substituted quinoline and naphthyridine compounds Active 22-Aug-2007
US-8143276-B2 4-thio substituted quinoline and naphthyridine compounds Inactive 22-Aug-2007 C07D215/36
To view Xtl Biopharmaceuticals’s complete patent history, request access »

Xtl Biopharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Xtl Biopharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Xtl Biopharmaceuticals‘s full profile, request access.

Request a free trial

Xtl Biopharmaceuticals Investments & Acquisitions (7)

Xtl Biopharmaceuticals’s most recent deal was a Merger/Acquisition with PsygaBio. The deal was made on 30-Jun-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
PsygaBio 30-Jun-2026 Merger/Acquisition Drug Discovery
NeuroNOS 13-Jan-2026 Merger/Acquisition Drug Discovery
The Social Proxy 14-Aug-2024 Merger/Acquisition Database Software
Geffen Residence & Renewal 21-Nov-2012 Secondary Transaction - Open Market Drug Discovery
InterCure 25-Jul-2012 Merger/Acquisition Pharmaceuticals
You’re viewing 5 of 7 investments and acquisitions. Get the full list »

Xtl Biopharmaceuticals ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Xtl Biopharmaceuticals’s complete esg history, request access »

Xtl Biopharmaceuticals Exits (3)

Xtl Biopharmaceuticals’s most recent exit was on 14-Aug-2024 from The Social Proxy. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
The Social Proxy 14-Aug-2024 Completed
Geffen Residence & Renewal 21-Nov-2012 Completed
IviGene 12-Mar-2001 Corporate Completed
To view Xtl Biopharmaceuticals’s complete exits history, request access »

Xtl Biopharmaceuticals Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
PsygaBio Caesarea, Israel 2021
InterCure Herzliya, Israel 1994

Xtl Biopharmaceuticals FAQs

  • When was Xtl Biopharmaceuticals founded?

    Xtl Biopharmaceuticals was founded in 1993.

  • Where is Xtl Biopharmaceuticals headquartered?

    Xtl Biopharmaceuticals is headquartered in Ramat Gan, Israel.

  • What is the size of Xtl Biopharmaceuticals?

    Xtl Biopharmaceuticals has 5 total employees.

  • What industry is Xtl Biopharmaceuticals in?

    Xtl Biopharmaceuticals’s primary industry is Drug Discovery.

  • Is Xtl Biopharmaceuticals a private or public company?

    Xtl Biopharmaceuticals is a Public company.

  • What is Xtl Biopharmaceuticals’s stock symbol?

    The ticker symbol for Xtl Biopharmaceuticals is XTLB.

  • What is the current market cap of Xtl Biopharmaceuticals?

    The current market capitalization of Xtl Biopharmaceuticals is $3.9M.

  • Who are Xtl Biopharmaceuticals’s competitors?

    Savara, Biocon, Novartis, Vicore Pharma Holding, and Lilly USA are some of the 21 competitors of Xtl Biopharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process